Searched for
ZEPBOUND REVENUE INCREASE
US stocks today: S&P 500 and Nasdaq hit record closing highs as US and Iran agree to extend ceasefireThe S&P 500 and Nasdaq hit record closing highs as hopes of a US Iran ceasefire extension boosted sentiment. Investors also digested US inf...- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- LLY stock jumps 9%: Why Eli Lilly stock is soaring today - Mounjaro, Zepbound sales drive massive earnings beat and 2026 forecast stuns Wall StreetLLY stock today: Eli Lilly's stock saw a significant jump following impressive fourth-quarter results and a strong 2026 financial forecast....
- US stock market slips again today: Why Dow, S&P 500 and Nasdaq are down for a second straight day as gold and silver prices surgeUS stock market slips again today. Dow, S&P 500 and Nasdaq are down for a second straight day. The Dow Jones Industrial Average slipped 83....
- Eli Lilly becomes first healthcare firm to hit $1 trillion market cap - here’s why LLY stock has jumped over 36% this yearEli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...
- Is US stock market down today? Why is the US stock market crashing today — S&P 500 and Nasdaq fall big while Dow Jones gainsUS stock market today live update analysis news: The S&P 500 fell 0.3% to 5,018. Nasdaq sank 0.6% to 15,170 as Meta plunged 11% after weak ...
- Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial missLilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...
- US stocks tick higher on tariff exemption hopesWall Street sees a surge in stocks despite President Trump's new tariffs. The S&P 500 nears a record high. The Dow Jones Industrial Average...
- Microsoft layoffs mount as it cuts 40 jobs - 3,160 fired in Washington since May, employees call it a cultural crisisMicrosoft layoffs Washington 2025: Microsoft continues job cuts in Washington state. This brings the total layoffs to 3,160 this year. Thes...
- US stocks close higher, lifted by Microsoft, Meta earningsU.S. stocks surged, with the Dow and S&P 500 achieving their eighth consecutive session of gains, fueled by robust earnings from Microsoft ...
- Pharma companies expected to absorb any tariff hit in short termU.S. tariffs on pharmaceuticals are unlikely to immediately raise brand-name drug prices, as drugmakers are expected to absorb initial cost...
- Pfizer scraps weight loss pill after liver injury: What it means for the future of obesity drugs?Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting its ambition ...
- Trump tariff threats prompt some drugmakers to expedite shipments to USFearing potential tariffs from President Trump's announcement, some European drugmakers are increasing air shipments of medications to the ...
- Tech rally drives S&P 500, Nasdaq to record highs; Powell comments in focusWall Street's main indexes climbed on Wednesday, with the S&P 500 and Nasdaq hitting record highs, fueled by tech stocks. Investors awaited...
- Zepbound: The new weight loss pill that’s set to beat Wegovy, according to Eli LillyEli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on average. While ...
- Lilly lifts sales forecast by $3 billion as weight-loss drug powers resultsAnalysts have said the companies will likely split the U.S. market roughly 50-50 by the end of 2024, as Lilly bolsters its manufacturing ca...
- Ozempic frenzy lures rich Indians to brave the gray marketPeople are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying coun...
- Eli Lilly rises 6%; company raises 2024 sales forecast by $2 billionExplosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales...
Load More
